Replies to post #15707 on Momenta Pharmaceuticals, Inc. (MNTA)

[marthambles]

And then some.

[Regulardoc]

While I realize developing new drugs and new drug candidates is a crap shoot, MNTA simply does not have a good track record in selecting viable candidates. Clearly the sample pool is small, but M118 was likewise a very poor candidate in a relatively crowded and limited use field at the time.